NGM Biopharmaceuticals, Inc.
Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions

Last updated:

Abstract:

Provided herein are variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

Status:
Grant
Type:

Utility

Filling date:

27 May 2015

Issue date:

3 Sep 2019